Edwards Lifesciences to Acquire Innovalve

Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) has announced its decision to acquire Innovalve Bio Medical , an early-stage transcatheter mitral valve replacement (TMVR) company. This move follows Edwards' initial investment in Innovalve in 2017 and is based on the company's promising early clinical experience. The acquisition aims to enhance Edwards' TMVR technologies, addressing unmet structural heart patient needs and supporting long-term growth.

Innovalve will join Edwards' transcatheter mitral and tricuspid therapies (TMTT) product group. The company's SAPIEN M3 is expected to become the first approved transfemoral TMVR system in Europe by the end of 2025. Edwards believes that combining Innovalve's technologies with its own mitral expertise will expand the treatable population for TMVR. The acquisition is set to close by the end of 2024.

Positive

• Acquisition of Innovalve enhances Edwards' TMVR technologies
• SAPIEN M3 on track to be first approved transfemoral TMVR system in Europe by end of 2025
• Expansion of treatable population for TMVR expected
• Strengthens Edwards' position in structural heart disease market

Negative

• None.

Financial Analyst

Edwards Lifesciences acquisition of Innovalve Bio Medical Ltd. indicates a strategic move to bolster its transcatheter mitral valve replacement (TMVR) portfolio. Financially, this acquisition presents the potential for significant long-term growth by addressing large unmet needs in the structural heart disease market. Innovalve's early clinical successes suggest a promising outlook for the TMVR technologies that could translate into substantial revenue streams once regulatory approvals are secured.

Short-term implications: While the acquisition cost isn’t disclosed, the impact on Edwards’ financials will depend on the integration efficiency and continued clinical success of Innovalve's technologies. Investors may initially observe a dip in earnings due to acquisition costs and integration expenses.

Long-term benefits: Edwards' existing expertise combined with Innovalve’s technology could position the company as a leader in the TMVR market. The mention of the SAPIEN M3 system's potential approval by 2025 in Europe is an added catalyst for future growth, reinforcing Edwards' market dominance. This acquisition aligns well with Edwards' strategic focus on innovation in heart valve therapies and could substantially expand its market share.

Medical Research Analyst

The acquisition of Innovalve reflects Edwards Lifesciences' commitment to advancing the treatment of mitral and tricuspid valve diseases. Mitral valve disease is complex and requires differentiated therapies. Innovalve’s early clinical success indicates promising advancements in transcatheter mitral valve replacement (TMVR) technologies, which are critical for patients who are not candidates for traditional surgical interventions.

Clinical implications: The integration of Innovalve’s technology with Edwards' SAPIEN M3 system could result in a comprehensive TMVR platform, potentially improving patient outcomes and expanding the treatable population. This is particularly significant given the unmet needs in the structural heart disease market. Furthermore, the synergy between the companies may accelerate the development and commercialization of new TMVR therapies, enhancing Edwards’ clinical pipeline.

Market impact: As Edwards continues to build on its strong clinical evidence base, this acquisition could accelerate the adoption of transcatheter therapies, setting new standards in the treatment of mitral and tricuspid valve diseases. This long-term vision highlights Edwards' strategy to remain at the forefront of cardiovascular innovation.

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience.

Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth. Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president, Daveen Chopra.

“Building on our learnings of the complexity of mitral disease, we know there is a need for a differentiated range of therapies for these patients,” said Chopra. “Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025. We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population.”

Edwards is developing a portfolio of transcatheter repair and replacement therapies designed to address mitral and tricuspid valve diseases. The company is committed to transforming the treatment of mitral and tricuspid patients, supported by a robust body of clinical evidence.

The acquisition is expected to close by the end of 2024.

About Edwards Lifesciences

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit www.edwards.com and follow us on Facebook, Instagram, LinkedIn, X and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this Proxy Statement to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by Mr. Chopra and statements regarding expected technology performance, product and therapy benefits, patient outcomes, treatable population, probability of approval by government authorities in Europe, performance of Innovalve’s technology as a basis for or in support of a TMVR platform, synergy between Innovalve’s technology and products and Edwards’ expertise, products, and operations, Edwards’ commitment to developing a portfolio of transcatheter repair and replacement therapies and to expanding or transforming patients’ treatments, other objectives and expectations, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include, but are not limited to: (i) Edwards may be unable to close the acquisition of Innovalve in a timely manner or at all, which may materially and adversely affect Edwards’ business and the price of Edward’ common stock; (ii) uncertainty as to the timing of closing of the acquisition of Innovalve; (iii) the occurrence of any event, change or other circumstance that could cause Edwards to abandon the acquisition of Innovalve; (iv) risks related to disruption of management’s attention from Edwards’ ongoing business operations; (v) the effect of the announcement or the pendency of the acquisition of Innovalve on Edwards’ relationships with its customers, operating results and business generally; (vi) potential significant transaction costs associated with the acquisition of Innovalve; (vii) the outcome of any legal proceedings or regulatory actions to the extent initiated against Edwards or others related to the acquisition of Innovalve; (viii) the ability of Edwards to execute on its strategy and achieve its goals and other expectations after the closing of the acquisition of Innovalve; (ix) legal, regulatory, tax and economic developments affecting Edwards’ business; (x) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism, outbreak of war or hostilities or current or future pandemics or epidemics, as well as Edwards’ response to any of the aforementioned factors; and (xi) other risks detailed in Edwards’ filings with the SEC, which may be found at edwards.com.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN M3, SAPIEN, and SAPIEN M3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715027456/en/

Media Contact: Loree Bowen, 949-250-0554

Investor Contact: Mark Wilterding, 949-250-6826

Source: Edwards Lifesciences Corporation

FAQ

What company is Edwards Lifesciences (EW) acquiring?

Edwards Lifesciences (EW) is acquiring Innovalve Bio Medical , an early-stage transcatheter mitral valve replacement (TMVR) company.

When did Edwards Lifesciences (EW) initially invest in Innovalve?

Edwards Lifesciences (EW) made its initial investment in Innovalve in 2017.

When is Edwards Lifesciences' (EW) SAPIEN M3 expected to be approved in Europe?

Edwards Lifesciences' (EW) SAPIEN M3 is expected to become the first approved transfemoral TMVR system in Europe by the end of 2025.

When is the acquisition of Innovalve by Edwards Lifesciences (EW) expected to close?

The acquisition of Innovalve by Edwards Lifesciences (EW) is expected to close by the end of 2024.